Leigh Charvet Selected Research

Transcranial Direct Current Stimulation

1/2023	Remotely supervised at-home tDCS for veterans with persistent post-traumatic headache: a double-blind, sham-controlled randomized pilot clinical trial.
1/2023	Non-invasive brain stimulation for fatigue in post-acute sequelae of SARS-CoV-2 (PASC).
11/2022	Combination of transcranial direct current stimulation with online cognitive training improves symptoms of Post-acute Sequelae of COVID-19: A case series.
5/2022	Tolerability and feasibility of at-home remotely supervised transcranial direct current stimulation (RS-tDCS): Single-center evidence from 6,779 sessions.
1/2022	Transcranial Electrical Stimulation for Psychiatric Disorders in Adults: A Primer.
5/2021	No risk of skin lesion or burn with transcranial direct current stimulation (tDCS) using standardized protocols.
1/2021	A Systematic Review and Meta-Analysis on the Efficacy of Repeated Transcranial Direct Current Stimulation for Migraine.
11/2020	Walking in multiple sclerosis improves with tDCS: a randomized, double-blind, sham-controlled study.
1/2020	Delivering Transcranial Direct Current Stimulation Away From Clinic: Remotely Supervised tDCS.
12/2018	Generalizing remotely supervised transcranial direct current stimulation (tDCS): feasibility and benefit in Parkinson's disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Leigh Charvet Research Topics

Disease

8	Multiple Sclerosis 04/2022 - 12/2015
2	Fatigue 01/2023 - 12/2018
2	Pruritus (Itching) 05/2022 - 12/2018
2	COVID-19 04/2022 - 07/2020
2	Pain (Aches) 01/2021 - 12/2015
2	Parkinson Disease (Parkinson's Disease) 12/2018 - 11/2018
2	Cognitive Dysfunction 12/2018 - 11/2018
1	Headache (Headaches) 01/2023
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2023
1	Post-Traumatic Headache 01/2023
1	Post-Acute COVID-19 Syndrome 11/2022
1	Infections 04/2022
1	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2022
1	Schizophrenia (Dementia Praecox) 01/2022
1	Mental Disorders (Mental Disorder) 01/2022
1	Substance-Related Disorders (Drug Abuse) 01/2022
1	Depressive Disorder (Melancholia) 01/2022
1	Burns 05/2021
1	Migraine Disorders (Migraine) 01/2021
1	Nervous System Diseases (Neurological Disorders) 12/2018
1	Brain Injuries (Brain Injury) 09/2016

Drug/Important Bio-Agent (IBA)

5	salicylhydroxamic acid (SHAM)IBA 01/2023 - 11/2020
2	TESIBA 01/2022 - 07/2020
1	Therapeutic UsesIBA 01/2023
1	Rituximab (Mabthera)FDA Link 04/2022
1	Natalizumab (Tysabri)FDA Link 04/2022
1	Dimethyl FumarateIBA 04/2022
1	Sphingosine-1-Phosphate ReceptorsIBA 04/2022
1	Fingolimod Hydrochloride (FTY720)FDA Link 04/2022
1	diroximel fumarateIBA 04/2022
1	FumaratesIBA 04/2022
1	siponimodIBA 04/2022
1	ocrelizumabIBA 04/2022
1	Indicators and Reagents (Reagents)IBA 01/2021
1	SolutionsIBA 01/2021

Therapy/Procedure

14	Transcranial Direct Current Stimulation 01/2023 - 12/2015
4	Cognitive Training 11/2022 - 06/2018
3	Therapeutics 01/2023 - 11/2018
2	Electrodes (Electrode) 05/2022 - 12/2018